Ipsen To Acquire ImCheck Therapeutics From EQT Life Sciences In Deal Valued Up To €1 Billion

Ipsen Acquires Epizyme to Expand Oncology Portfolio

August 12, 2022

Pharmaceuticals

Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.

Sun Pharma Acquires Checkpoint Therapeutics

May 30, 2025

Biotechnology

Sun Pharmaceutical Industries Limited has completed the acquisition of Checkpoint Therapeutics, Inc., acquiring all outstanding shares for $4.10 per share in cash plus a contingent value right. The deal gives Sun Pharma ownership of UNLOXCYT (cosibelimab-ipdl), the FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma, and expands its oncology/onco-derm product portfolio.

Regeneron Acquires Checkmate Pharmaceuticals

April 19, 2022

Biotechnology

Regeneron Pharmaceuticals agreed to acquire Checkmate Pharmaceuticals in an all-cash transaction valuing Checkmate at approximately $250 million (at $10.50 per share). The acquisition brings Checkmate's lead investigational immune activator, vidutolimod (a VLP-delivered TLR9 agonist), into Regeneron’s immuno-oncology portfolio to accelerate development and enable combination strategies across tumor types.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.